Salarius Pharmaceuticals, Inc. (SLRX) |
|
1.72 0.07 (4.24%)
|
06-06 15:18 |
|
Open: |
1.6499 |
Pre. Close: |
1.65 |
|
High:
|
1.8 |
Low:
|
1.62 |
|
Volume:
|
99,895 |
Market Cap:
|
6(M) |
|
|
|
Technical analysis |
as of: 2023-06-06 2:51:13 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
|
| Target: |
Six months: 2.22 One year: 2.69 |
| Support: |
Support1: 1.25 Support2: 1.03 |
| Resistance: |
Resistance1: 1.9 Resistance2: 2.3 |
| Pivot: |
1.49  |
| Moving Average: |
MA(5): 1.56 MA(20): 1.49 
MA(100): 1.97 MA(250): 3.13 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 86.6 %D(3): 80.3 |
| RSI: |
RSI(14): 57.8 |
| 52-week: |
High: 7.19 Low: 1.07 |
| Average Vol(K): |
3-Month: 102 (K) 10-Days: 42 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SLRX ] has closed Bollinger Bands are 55% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.65 - 1.66 |
1.66 - 1.67 |
|
Low:
|
1.54 - 1.55 |
1.55 - 1.56 |
|
Close:
|
1.6 - 1.61 |
1.61 - 1.63 |
|
Company Description |
|
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas. |
Headline News |
Thu, 11 May 2023
Salarius: Q1 Earnings Snapshot - Houston - Chron
Thu, 11 May 2023
Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update - Yahoo Finance
Tue, 09 May 2023
Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood - MarketWatch
Tue, 09 May 2023
Salarius Pharmaceuticals Inc (SLRX) Stock: What Does the Chart Say Tuesday? - InvestorsObserver
Thu, 20 Apr 2023
Salarius Pharmaceuticals Presents Compelling Data in Two SP ... - GlobeNewswire
Tue, 04 Apr 2023
Salarius Pharmaceuticals to Present at the Diamond Equity ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
3 (M) |
| Shares Float |
2 (M) |
|
% Held by Insiders
|
7.6 (%) |
|
% Held by Institutions
|
10.3 (%) |
|
Shares Short
|
95 (K) |
|
Shares Short P.Month
|
128 (K) |
Stock Financials |
|
EPS
|
-15.56 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.25 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-61.2 |
|
Return on Equity (ttm)
|
-158.3 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-4.73 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-6.66 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-17 (M) |
|
Levered Free Cash Flow
|
-11 (M) |
Stock Valuations |
|
PE Ratio
|
-0.11 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.75 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.34 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
